The Alter Pharma Group is Becoming A.forall

Milla Pharmaceutical Inc., a subsidiary of the Alter Pharma Group, is now becoming an A.forall company - The Alter Pharma Group, a group of generic and pharmacy sales companies, is rebranding all its brands and businesses into A.forall. This change, starting 27 September, represents an important milestone in A. forall’s pursuit of a world where patients can access high-quality, safe and innovative medicines at an affordable price. The move strengthens A.forall’s commitment to #MakingAffordableMedicinesAvailableToAll, offering new synergies and ways to leverage the skills and capacities of its 144 employees around the world. Milla Pharmaceuticals, now an A.forall company, is proud to be part of this transition.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230927472871/en/

Alter Pharma started pharmacy sales in 2006. In 2010, it became the Alter Pharma Group after the consolidation of several entities and last year, the group reached an important milestone with its first major acquisition. Its generics business currently markets more than 30 in-house developed added value products that are being sold in more than 60 countries around the globe including US, whereas A.forall’s Benelux Pharmacy House provides medicine shortage services through hospital and retail pharmacies. In 2022 alone, by helping pharmacists to source medicines in shortage, the group managed to bring relief to more than 100,000 hospitalized patients and to supply more than 650,000 months of missing treatments to patients that would otherwise be lacking their medication.

Throughout this journey, the Alter Pharma Group and its brands have always been focused on delivering secure access to high-quality, affordable medicines. The current rebranding will unify businesses and commercial brands of the group*, countless stories and talents, while continuing to make sure that no one is left behind in the pursuit of better health and well-being.

“The Alter Pharma Group has been going through a period of incredible evolution and innovation over the past years. We could not be more excited about the next step: our rebranding to A.forall. We’re coming together better and stronger than ever in order to deliver on our mission of Making Affordable Medicines Available To All.”

-Filip Van de Vliet, Chief Executive Officer

A.forall stands for each of the key motivations behind our mission. It stands for Accessible – fostering patient access to superior healthcare solutions that are affordable and available for everyone. It stands for Assurance – an unwavering commitment to ensure the utmost reliability, trust, and adherence to the highest quality and safety standards. And it stands for All – our entire team is unified by a single mission of delivering high-quality and affordable healthcare solutions to all. By all, to all, for all.

For the full press release and more information on the rebranding, check out the full communication on our website or directly in this article.

www.aforallpharma.com

Note to editors:

A.forall, previously known as Alter Pharma or the Alter Pharma Group, is a Belgian group of pharmaceutical companies with headquarters in Anderlecht (Belgium) and offices in Ireland and the United States. Employing in total over 144 employees, the company distributes a wide range of pharmaceutical products to pharmacies, wholesalers, hospitals, and retirement homes. At the same time, A.forall is a global player on the generics market, with 30+ molecules on the European and US market and a fully stocked pipeline of niche, complex and added value products.

Milla Pharmaceuticals Inc., an A.forall company and wholly-owned subsidiary of the group, is engaged in the development, licensing, acquisition, and commercialization of generic prescription drugs for the US market focused on niche injectable and solution products for hospitals and clinics

*A.forall was formerly known as: Active Pharma, Accure Pharma, Alter Pharma, Eco.Pharma.Supply, GPI, GSP, Impexeco, Medi Group, Milla Pharmaceuticals, Neogen

View source version on businesswire.com: https://www.businesswire.com/news/home/20230927472871/en/